CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Herombopagdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05660785
NCT05660785Phase 2Completed
CompareCT.gov

The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia

Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Dec 21, 2022·Updated Aug 5, 2025

In Brief

A Phase 2 clinical trial evaluating Herombopag for Non Severe Aplastic Anemia and Untreated. Completed, enrolled 54 participants across 4 sites.

Detailed Summary

This is a prospective, multicenter, single-arm, phase 2 trial. The aim of this study is to evaluate the efficacy and safety of herombopag combined with cyclosporine for patients with non severe aplastic anemia (NSAA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Severe Aplastic Anemia, Untreated
CountriesChina
CollaboratorsJiangsu Hengrui Pharmaceutical Co., Ltd.

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedDec 21, 2022
Enrollment StartDec 1, 2022
Primary CompletionJan 20, 2025
Study CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.5 years ago

Interventions

Herombopagdrug

Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT. Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.